TRIAD - Treatment of Insomnia and Depression

Not Recruiting

Trial ID: NCT00767624


The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Official Title

Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants

Stanford Investigator(s)

Rachel Manber, PhD
Rachel Manber, PhD

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult)


Inclusion Criteria:

   1. Meets criteria for Major Depressive Disorder

   2. Between 18 and 75 years of age and adequately fluent in English

   3. Meets criteria for an insomnia disorder

Exclusion Criteria:

   1. Women who are currently pregnant, breast-feeding, or not using a reliable birth
   control method.

   2. People for whom the antidepressant medication(s) provided in the study is not

   3. People who have had minimum adequate trials of (or have not been able to tolerate) all
   three study medications.

   4. People with uncontrolled medical conditions.

   5. People with moderate or severe sleep disorders other than insomnia

   6. Individuals on a fixed night shift or rotating work schedule that requires a night

   7. Patients with a current principal diagnosis of a psychiatric disorder that
   necessitates treatment that is not offered in the study.


drug: Antidepressant

behavioral: Desensitization Therapy for Insomnia

behavioral: Cognitive Behavioral Therapy for Insomnia

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305